Shringi Sharma

9PUBLICATIONS
67CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 30, 2026
Learnings from Approved Antibody-Drug Conjugates: Clinical Pharmacology Perspectives.

Bhargavi Thalluri, Aarti Sawant, Pavan Vajjah

|Feb 24, 2025
Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B-cell malignancies.

Tingting Yao, Junjie Ding, Shringi Sharma

|Aug 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.

Pinkal Desai, Sagar Lonial, Amanda Cashen

|Jun 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Mark Roschewski, Manish R Patel, Patrick M Reagan

|Feb 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.

Julio C Chavez, Francine M Foss, Basem M William

|Apr 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.

Shringi Sharma, Xavier Pepin, Jean Cheung

Pageof 2

Frequent Collaborators

3 joint publications

Karthick Vishwanathan

2 joint publications

Helena Edlund

2 joint publications

Ian Flinn

1 joint publications

Buyun Chen